BPMC Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -34.13% compared to Blueprint Medicines's net margin of -14.12%. Blueprint Medicines's return on equity of -24.43% beat Alnylam Pharmaceuticals's return on equity of --.

Blueprint Medicines has a consensus price target of $126.48, signalling upside risk potential of 40.95%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $311.24 which suggests that it could grow by 14.84%. Given that Blueprint Medicines has higher upside potential than Alnylam Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Alnylam Pharmaceuticals.

Blueprint Medicines has a beta of 0.575, which suggesting that the stock is 42.472% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.76%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Blueprint Medicines's net income of -$50M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.18x versus 15.39x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -34.13% compared to Blueprint Medicines's net margin of 16.72%. Blueprint Medicines's return on equity of -24.43% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Blueprint Medicines has a consensus price target of $126.48, signalling upside risk potential of 40.95%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.72 which suggests that it could grow by 32.81%. Given that Blueprint Medicines has higher upside potential than Biomarin Pharmaceutical, analysts believe Blueprint Medicines is more attractive than Biomarin Pharmaceutical.

Blueprint Medicines has a beta of 0.575, which suggesting that the stock is 42.472% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Blueprint Medicines's net income of -$50M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 33.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.18x versus 5.06x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -34.13% compared to Blueprint Medicines's net margin of -2357.27%. Blueprint Medicines's return on equity of -24.43% beat Palatin Technologies's return on equity of --.

Blueprint Medicines has a consensus price target of $126.48, signalling upside risk potential of 40.95%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 900%. Given that Palatin Technologies has higher upside potential than Blueprint Medicines, analysts believe Palatin Technologies is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.575, which suggesting that the stock is 42.472% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Palatin Technologies quarterly revenues of $350K. Blueprint Medicines's net income of -$50M is lower than Palatin Technologies's net income of -$2.4M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.18x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -34.13% compared to Blueprint Medicines's net margin of --. Blueprint Medicines's return on equity of -24.43% beat Viking Therapeutics's return on equity of --.

Blueprint Medicines has a consensus price target of $126.48, signalling upside risk potential of 40.95%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 276.97%. Given that Viking Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Viking Therapeutics is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.575, which suggesting that the stock is 42.472% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Viking Therapeutics quarterly revenues of --. Blueprint Medicines's net income of -$50M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.18x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.